Fulgent Genetics, Inc. (FLGT)
NASDAQ: FLGT · Real-Time Price · USD
20.00
+0.36 (1.83%)
Jul 30, 2026, 12:47 PM EDT - Market open
Fulgent Genetics Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 320.35 | 322.67 | 283.47 | 289.21 | 618.97 | 992.58 |
Revenue Growth | 9.54% | 13.83% | -1.99% | -53.27% | -37.64% | 135.37% |
Gross Profit Gross Profit Growth | 124.02 | 130.88 | 107.22 | 104.46 | 366.9 | 777.05 |
Operating Income Operating Income Growth | -105.92 | -91.1 | -73.92 | -195.53 | 178.53 | 675.95 |
Net Income Net Income Growth | -73.81 | -60.51 | -42.71 | -167.83 | 143.4 | 507.36 |
Earnings Per Share EPS Growth | -2.39 | -1.97 | -1.41 | -5.63 | 4.63 | 16.38 |
EPS Growth | - | - | - | - | -71.73% | 83.84% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Therapeutic Development Therapeutic Development Growth | - | 0.45 | - | - | - | - |
Laboratory Services Laboratory Services Growth | 319.81 | 322.22 | 283.47 | 289.21 | 618.97 | 992.58 |
Total Total Growth | 320.35 | 322.67 | 283.47 | 289.21 | 618.97 | 992.58 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 276.3 | 336.08 | 258.11 | 424.15 | 526.24 | 450.5 |
Total Debt Total Debt Growth | 0.48 | 0.48 | 0.41 | 1.18 | 5.64 | 6.15 |
Net Cash (Debt) Net Cash Growth | 275.82 | 335.6 | 257.69 | 422.97 | 520.6 | 444.35 |
Net Cash Growth | -13.76% | 30.23% | -39.07% | -18.75% | 17.16% | 48.43% |
Net Cash Per Share Net Cash Per Share Growth | 8.96 | 10.90 | 8.52 | 14.20 | 16.81 | 14.35 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -89.15 | -101.64 | 21.06 | 27 | 253.52 | 538.58 |
Capital Expenditures CapEx Growth | -23.06 | -22.57 | -40.32 | -22.21 | -18.78 | -23.81 |
Free Cash Flow Free Cash Flow Growth | -112.21 | -124.21 | -19.26 | 4.8 | 234.75 | 514.77 |
Free Cash Flow Growth | - | - | - | -97.96% | -54.40% | 387.94% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 38.71% | 40.56% | 37.82% | 36.12% | 59.28% | 78.29% |
Operating Margin | -33.07% | -28.23% | -26.08% | -67.61% | 28.84% | 68.10% |
Pretax Margin | -26.31% | -21.70% | -18.33% | -60.19% | 29.73% | 68.24% |
Profit Margin | -23.41% | -19.10% | -15.46% | -60.59% | 22.93% | 51.00% |
FCF Margin | -35.03% | -38.49% | -6.79% | 1.66% | 37.93% | 51.86% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 6.43 | 6.14 |
Forward PE | - | 247.16 | 247.16 | 247.16 | 247.16 | 13.80 |
P/FCF Ratio | - | - | - | 178.75 | 3.73 | 5.89 |
PS Ratio | 1.75 | 2.53 | 2.01 | 2.96 | 1.42 | 3.06 |